Nature of the Business and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Potential Dilutive Securities

The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:

	As of June 30,
	2020	2019
Options to purchase common stock	7,073,775	6,891,799
Unvested time-based restricted common stock units	409,955	77,000
Unvested performance-based restricted common stock units	57,000	—
Unvested employee stock purchase plan shares	39,600	—
Total	7,580,330	6,968,799

Schedule of Inventory

The Company commenced the capitalization of QINLOCK inventory in May 2020 upon receiving FDA approval of QINLOCK. Capitalized inventory consisted of the following:

(in thousands)	As of June 30, 2020
Raw materials	$	765
Work in process	624
Total inventory	$	1,389